SI3227454T1 - Postopek za manipuliranje ravni vsebnosti glikana glikoproteina - Google Patents

Postopek za manipuliranje ravni vsebnosti glikana glikoproteina

Info

Publication number
SI3227454T1
SI3227454T1 SI201531140T SI201531140T SI3227454T1 SI 3227454 T1 SI3227454 T1 SI 3227454T1 SI 201531140 T SI201531140 T SI 201531140T SI 201531140 T SI201531140 T SI 201531140T SI 3227454 T1 SI3227454 T1 SI 3227454T1
Authority
SI
Slovenia
Prior art keywords
glycoprotein
manipulating
level
glycan content
glycan
Prior art date
Application number
SI201531140T
Other languages
English (en)
Slovenian (sl)
Inventor
Daniel R. Leiske
Michael T. Trentalange
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3227454(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of SI3227454T1 publication Critical patent/SI3227454T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201531140T 2014-12-01 2015-12-01 Postopek za manipuliranje ravni vsebnosti glikana glikoproteina SI3227454T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein
EP15816598.5A EP3227454B1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (1)

Publication Number Publication Date
SI3227454T1 true SI3227454T1 (sl) 2020-06-30

Family

ID=55024253

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531140T SI3227454T1 (sl) 2014-12-01 2015-12-01 Postopek za manipuliranje ravni vsebnosti glikana glikoproteina

Country Status (22)

Country Link
US (5) US10167492B2 (OSRAM)
EP (2) EP3227454B1 (OSRAM)
JP (4) JP6698681B2 (OSRAM)
KR (1) KR102623965B1 (OSRAM)
CN (1) CN107109455B (OSRAM)
AU (5) AU2015355087C1 (OSRAM)
CA (1) CA2969225C (OSRAM)
CL (1) CL2017001369A1 (OSRAM)
CY (1) CY1123247T1 (OSRAM)
DK (1) DK3227454T3 (OSRAM)
EA (2) EA036178B1 (OSRAM)
ES (1) ES2784503T3 (OSRAM)
HU (1) HUE049201T2 (OSRAM)
IL (2) IL276165B (OSRAM)
LT (1) LT3227454T (OSRAM)
MX (1) MX385409B (OSRAM)
PL (1) PL3227454T3 (OSRAM)
PT (1) PT3227454T (OSRAM)
SG (2) SG10202002458PA (OSRAM)
SI (1) SI3227454T1 (OSRAM)
WO (1) WO2016089919A1 (OSRAM)
ZA (2) ZA201703729B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
US11719704B2 (en) 2015-12-30 2023-08-08 Momenta Pharmaceuticals, Inc. Methods related to biologics
CA3056011A1 (en) * 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
AU2018241849B2 (en) * 2017-03-31 2023-06-22 Boehringer Ingelheim International Gmbh Perfusion medium
CN111373028B (zh) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
CN112272708A (zh) * 2018-05-24 2021-01-26 阿雷斯贸易股份有限公司 控制糖蛋白组合物去岩藻糖基化水平的方法
WO2019236739A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
EP3850006A1 (en) 2018-09-11 2021-07-21 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
SG11202104092UA (en) 2018-11-13 2021-05-28 Janssen Biotech Inc Control of trace metals during production of anti-cd38 antibodies
CN113474366B (zh) 2018-12-31 2025-01-17 动量制药公司 产生优特克单抗的方法
EP3917951A1 (en) * 2019-01-30 2021-12-08 Amgen, Inc Aflibercept attributes and methods of characterizing and modifying thereof
KR20230002024A (ko) 2019-05-06 2023-01-05 암젠 인크 항체 효과기 기능의 조절
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CA3251442A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc METHOD FOR IMPROVING POLYPEPTIDE EXPRESSION IN A MAMMALIAN CELL CULTURE
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
UA87432C2 (uk) 2000-05-26 2009-07-27 Бристол-Майерс Сквибб Компани Розчинний мутантний ctla4 та його застосування
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
HUE026403T2 (en) 2007-03-02 2016-06-28 Wyeth Llc Use of copper and glutamate in cell culture to produce polypeptides
AU2008232699A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. High expression clones of mammalian cells with fluorescent protein A or G
BRPI0810471A2 (pt) 2007-04-16 2014-11-11 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
MX2009013762A (es) 2007-06-15 2010-03-01 Amgen Inc Metodos para tratar medios de cultivo de celulas para uso en biorreactor.
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
EP2629798A4 (en) * 2010-10-20 2014-05-28 Morphotek Inc GLYCOFORMS OF ANTI-RECEPTOR ANTIBODY-ALPHA FOLATE (ANTI-FRA)
MX2013009741A (es) 2011-02-23 2014-01-17 Amgen Inc Medio de cultivo celular para exposicion a uvc y metodos relacionados al mismo.
EP2683821B1 (en) * 2011-03-06 2018-07-25 Merck Serono SA Low fucose cell lines and uses thereof
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) * 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
IL288509B2 (en) 2011-07-01 2023-04-01 Amgen Inc Mammalian cell culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
WO2013040444A1 (en) 2011-09-16 2013-03-21 Amgen Inc. Pre-programmed non-feedback controlled continuous feeding of cell cultures
KR102091294B1 (ko) 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
EP2804946A4 (en) * 2012-01-20 2016-05-25 Agency Science Tech & Res RECOMBINANT CHO GMT PROTEIN EXPRESSION
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2905290B1 (en) * 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2014294618B2 (en) 2013-07-23 2019-06-27 Biocon Limited Methods for controlling fucosylation levels in proteins
KR102280638B1 (ko) * 2014-02-27 2021-07-22 에프. 호프만-라 로슈 아게 재조합 당단백질 제조에서의 세포 성장 및 글리코실화의 조절
SG11201702964UA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법

Also Published As

Publication number Publication date
MX2017006997A (es) 2017-10-16
US20170362625A1 (en) 2017-12-21
EA201791223A1 (ru) 2017-10-31
IL252569A0 (en) 2017-07-31
PL3227454T3 (pl) 2020-07-27
US20190085370A1 (en) 2019-03-21
WO2016089919A1 (en) 2016-06-09
JP2024095777A (ja) 2024-07-10
PT3227454T (pt) 2020-04-06
AU2022200586A1 (en) 2022-02-24
US20210017565A1 (en) 2021-01-21
IL276165B (en) 2022-11-01
JP6698681B2 (ja) 2020-05-27
US20200172947A1 (en) 2020-06-04
AU2015355087B2 (en) 2020-04-09
AU2025223948A1 (en) 2025-09-18
EP3227454B1 (en) 2020-01-29
US10822630B2 (en) 2020-11-03
US20230159974A1 (en) 2023-05-25
US10167492B2 (en) 2019-01-01
CA2969225A1 (en) 2016-06-09
CA2969225C (en) 2023-08-22
EP3227454A1 (en) 2017-10-11
IL276165A (en) 2020-09-30
CY1123247T1 (el) 2021-10-29
CL2017001369A1 (es) 2018-02-23
AU2024204313A1 (en) 2024-07-11
KR20170083636A (ko) 2017-07-18
SG10202002458PA (en) 2020-04-29
ES2784503T3 (es) 2020-09-28
SG11201704351WA (en) 2017-06-29
EP3680344A1 (en) 2020-07-15
JP7066775B2 (ja) 2022-05-13
ZA202006002B (en) 2022-03-30
CN107109455A (zh) 2017-08-29
BR112017011652A2 (pt) 2018-06-26
KR102623965B1 (ko) 2024-01-11
EA202091598A3 (ru) 2021-01-29
MX385409B (es) 2025-03-04
JP2020124216A (ja) 2020-08-20
AU2015355087C1 (en) 2025-10-30
HUE049201T2 (hu) 2020-09-28
EA202091598A2 (ru) 2020-10-30
AU2020202302A1 (en) 2020-04-23
IL252569B (en) 2020-08-31
ZA201703729B (en) 2021-03-31
CN107109455B (zh) 2022-02-18
DK3227454T3 (da) 2020-04-14
JP2017538446A (ja) 2017-12-28
AU2015355087A1 (en) 2017-06-29
LT3227454T (lt) 2020-07-27
EA036178B1 (ru) 2020-10-09
JP2022101669A (ja) 2022-07-06

Similar Documents

Publication Publication Date Title
ZA202006002B (en) Process for manipulating the level of glycan content of a glycoprotein
GB201413701D0 (en) Process
GB201405800D0 (en) Process
SG11201701502VA (en) A process for the production of adenovirus
GB201406890D0 (en) Process
GB201415862D0 (en) Process
GB201404468D0 (en) Process
GB201413340D0 (en) Process
GB201402950D0 (en) Process
GB2522599B (en) Process for separating materials
GB201409126D0 (en) Process
GB201402782D0 (en) Process
GB201400137D0 (en) Process
GB201412406D0 (en) Process
SG11201704523WA (en) A process for the manufacture of idalopirdine
GB201414292D0 (en) Process
GB201411627D0 (en) Process
GB201415972D0 (en) Process
GB201405209D0 (en) Process
GB201410174D0 (en) Process
GB201405929D0 (en) Process
GB201403057D0 (en) Process
IL252471A0 (en) A process for the production of idalopyridine
SG11201703297QA (en) Separation process
PL3113919T3 (pl) Sposób powlekania fragmentu powierzchni